Search

ATLANTA, June 5, 2006 - A new multicenter study is the first to suggest that the prophylactic removal of the ovaries and fallopian tubes may provide a different benefit for women who carry a genetic mutation in the BRCA2 gene than for those who have a BRCA1 genetic mutation. The results of the study, which are being presented today at the annual American Society of Clinical Oncology meeting, also provide the strongest evidence to date that this surgery significantly reduces the overall risk of BRCA-associated breast and ovarian cancers.

… Monday, June 5, 2006 A new multicenter study is the first to suggest that the prophylactic removal of the ovaries and fallopian tubes may provide a different benefit for women who carry a genetic mutation in the BRCA2 gene than for those who have a BRCA1 genetic mutation. The results of the study, which

Learn how a clinical trial for a new type of immunotherapy called TCR therapy benefited a patient with synovial sarcoma.

… Wednesday, July 16, 2025 It was hard enough the first time Conor Handley was diagnosed with cancer, at age 17. He had a rare soft tissue cancer called synovial sarcoma. Then three years after finishing treatment, early in his senior year of college, came the devastating news: His synovial sarcoma was

Learn how molecular analysis of Jason’s sarcoma led to a personalized immunotherapy treatment that dramatically improved his prognosis. MSK is a leader in treating sarcoma.

… Monday, July 18, 2022 Thirty-four-year-old Jason Mascolo put off getting the nagging pain in his leg checked out for years because he didn’t have health insurance. It wasn’t until he got a job with benefits — as a utility worker with Consolidated Edison — that he went to see a doctor. The news was not

Results from studies in cell cultures and mouse models suggest that the experimental targeted therapy PU-H71 may be effective against one of the most aggressive forms of breast cancer.

… Thursday, October 1, 2009 Summary Results from studies in cell cultures and mouse models suggest that the experimental targeted therapy PU-H71 may be effective against one of the most aggressive forms of breast cancer. Results from studies in cell cultures and mouse models suggest that the experimental

Dr. Tagore is a postdoctoral fellow in the Cancer Biology and Genetics Program at the Sloan Kettering Institute studying cell communication in cancer.

… Monday, June 8, 2020 Summary Mohita Tagore is a postdoctoral fellow in the Cancer Biology and Genetics Program at the Sloan Kettering Institute. She is a 2020 winner of a Kravis WISE postdoctoral fellowship and will be presenting her research at the inaugural Kravis WiSE Symposium on July 8, 2020. In

After immunotherapy and targeted therapy failed to bring a patient's melanoma under control, MSK doctors offered her a new treatment called tumor-infiltrating lymphocyte, or TIL, therapy.

… Tuesday, October 28, 2025 It was not the news that Pattie Fuller wanted to hear.  Doctors at a local hospital in upstate New York told her that despite surgery and several rounds of  immunotherapy , her  melanoma was growing. The melanoma ultimately grew to be stage 4. It spread from her scalp to the

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Wednesday, September 15, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: MSK Receives National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) Grant Omar Abdel-Wahab and Martin Tallman The National Cancer Institute (NCI) awarded

Despite significant advances in supportive care and improvements in allogeneic hematopoietic stem cell transplantationoutcomes, about one in every three patients succumbs to post-transplant toxicities, half of which are not related to graft-versus-host disease.

… Thursday, March 15, 2018 Despite significant advances in supportive care and improvements in allogeneic hematopoietic stem cell transplantation outcomes, about one in every three patients succumbs to post-transplant toxicities, half of which are not related to graft-versus-host disease (GVHD). While

Investigators found that olaparib extended progression-free survival by an average of three months in women with advanced breast cancer.

… Sunday, June 4, 2017 Summary A new trial of olaparib found that the drug extended progression-free survival by an average of three months in women with advanced breast cancer . Olaparib is in a class of drugs called PARP inhibitors. Update: On January 12, 2018 the FDA approved olaparib (Lynparza®) for

The US Food and Drug Administration (FDA) has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD). This is the first approval of a targeted therapy based on a basket study and the first-ever drug approved for ECD, a rare blood disorder. This landmark approval came as a direct result of research at Memorial Sloan Kettering Cancer Center (MSK).

… Monday, November 6, 2017 Bottom Line The US Food and Drug Administration (FDA) has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600 -mutant Erdheim-Chester disease (ECD). This is the first approval of a targeted therapy based on a basket study and the first-ever